Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

Autor: Christian Trepo, Michael P. Manns, David Wright, Jose Luis Calleja, Peter W. White, Chan-Loi Yong, Stanislas Pol, George Kukolj, Jerry O. Stern, Marc Bourlière, Maurizio Bonacini, Thomas Berg, Wulf Otto Boecher, Yves Benhamou, Gerhard G. Steinmann, Joe Scherer

Publikováno v: Journal of Hepatology
Journal of Hepatology, Elsevier, 2011, 54 (6), pp.1114-22. ⟨10.1016/j.jhep.2010.08.040⟩
Journal of Hepatology, Elsevier, 2011, 54 (6), pp.1114-22. 〈10.1016/j.jhep.2010.08.040〉

International audience; BACKGROUND & AIMS: BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients. METHODS: Thirty-four treatment-na�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::947da88215c342d73ca0ef790ae3bfd6
https://doi.org/10.1016/j.jhep.2010.08.040

1349 VIROLOGIC RELAPSE IS HIGHLY CORRELATED WITH RESPONSE AT WEEK 4 AND 12 BUT NOT WITH IL28B GENOTYPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH PEG-INTERFERON/RIBAVIRIN

Autor: E Schulte-Frohlinde, Christoph Sarrazin, Thomas Berg, Robert Thimme, Gerlinde Teuber, Peter Buggisch, Wulf Otto Boecher, Jens Encke, Bernd Möller, S. Schwendy, V. Weich, S. Zeuzem, Tobias Goeser, Nektarios Dikopoulos, Hartwig Klinker

Publikováno v: Journal of Hepatology. 54:S532-S533

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e274c7543143599e8a7049a004fb6be5
https://doi.org/10.1016/s0168-8278(11)61351-2

[604] COMPARISON OF A SHORTENED RIBAVIRIN TREATMENT VS A 24 WEEK STANDARD COMBINATION THERAPY IN HCV INFECTED PATIENTS WITH GENOTYPE 2/3

Autor: Birgit Kallinowski, Tobias Goeser, P. Haiss, K. Stein, Hartwig Klinker, Thomas Bruckner, Wulf Otto Boecher, Peter Buggisch, Ralph Link, Ulrich Spengler

Publikováno v: Journal of Hepatology. 46:S228-S229

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e1251a246d03ee876b27a6f998f0bae
https://doi.org/10.1016/s0168-8278(07)62202-8

1420 THE EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF BI201335 AND BI207127 IN GENOTYPE 1 HCV PATIENTS WITH CIRRHOSIS - INTERIM ANALYSIS FROM SOUND-C2

Autor: M.P. Manns, Vicente Soriano, Felix Stickel, Wulf Otto Boecher, Peter W Angus, Federico J. Mensa, E.J. Gane, S. Zeuzem, Jean-Pierre Bronowicki, Stuart K. Roberts, L. Dai, Jerry O. Stern

Publikováno v: Journal of Hepatology. 56:S559

1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN F.F. Poordad, E.J. Lawitz, K.R. Reddy,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::707117f53abdb56faef7cf59810d6948
https://doi.org/10.1016/s0168-8278(12)61431-7

483 IMPORTANCE OF HCV RNA ASSAY CHARACTERISTICS AND DIFFERENCES BETWEEN ASSAYS FOR RESPONSE GUIDED THERAPY OF CHRONIC HEPATITIS C

Autor: E Schulte-Frohlinde, Christoph Sarrazin, Wulf Otto Boecher, Thomas Berg, Nektarios Dikopoulos, Hartwig Klinker, Robert Thimme, S. Zeuzem, Gerlinde Teuber, S. Schwendy, Bernd Möller, Peter Buggisch, Tobias Goeser, Jens Encke, V. Weich

Publikováno v: Journal of Hepatology. 54:S198

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e19ee8149ada0c9a791b28b1a3f5e84
https://doi.org/10.1016/s0168-8278(11)60485-6